Tim Boyle/Getty Images News Abbott ( NYSE: ABT ) on Wednesday announced a global partnership to connect its continuous glucose monitoring system with Medtronic's ( NYSE: MDT ) automated insulin delivery (AID) and smart insulin pen systems. Financial terms of the partnership and timing for commercial availability were not disclosed. The integration of Abbott's CGM sensor with Medtronic's AID algorithms will enable automatic adjustments of insulin to keep glucose in range.
The CGM sensor, designed to work exclusively with Medtronic devices, will be developed by Abbott and sold by Medtronic. Abbott's ( ABT ) Libre single-analyte CGM technology is currently available and integrated with AID offerings from four other insulin delivery companies, including Novo Nordisk ( NVO ) -3.3% premarket, Insulet ( PODD ) -0.
18% and Tandem Diabetes ( TNDM ) -8% . Shares of fellow continuous glucose monitoring device maker DexCom ( DXCM ) also fell ~4% . More on Abbott Laboratories, Medtronic, etc.
Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors Abbott Laboratories (ABT) Q2 2024 Earnings Call Transcript Medtronic: Lock In This Dividend Aristocrat While It's Still Cheap Abbott to collaborate with Cadrenal on anticoagulant tecarfarin DexCom, Abbott to benefit from the multi-billion-dollar OTC continuous glucose market.
